CA2545860A1 - Device for treating osteoarthritis and cartilage disease, defects, and injuries in the human hip - Google Patents
Device for treating osteoarthritis and cartilage disease, defects, and injuries in the human hip Download PDFInfo
- Publication number
- CA2545860A1 CA2545860A1 CA002545860A CA2545860A CA2545860A1 CA 2545860 A1 CA2545860 A1 CA 2545860A1 CA 002545860 A CA002545860 A CA 002545860A CA 2545860 A CA2545860 A CA 2545860A CA 2545860 A1 CA2545860 A1 CA 2545860A1
- Authority
- CA
- Canada
- Prior art keywords
- current
- human
- hip joint
- voltage
- hip
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/326—Applying electric currents by contact electrodes alternating or intermittent currents for promoting growth of cells, e.g. bone cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
Abstract
A method of determining the voltage and current required for the application of specific and selective electric and electromagnetic signals to diseased articular cartilage in the treatment of osteoarthritis, cartilage defects due to trauma or sports injury, or used as an adjunct with other therapies (cell transplantation, tissue-engineered scaffold, growth factors, etc.) for treating cartilage defects in the human hip joint and a device for delivering such signals to a patient's hip. Anatomic, analytical, and planar circuit models are developed to determine the impedances, conductivities, and current flows in the human hip joint and its surrounding soft tissues and skin that are required to produce a 20mV/cm electric field in the synovium and articular cartilage of the human hip. The voltage of the signal applied to the surface electrodes (20) or to a coil(s) or solenoid is varied based on the size of the hip joint; larger hip joints require larger voltages to generate the effective electric field.
Description
METHOD AND DEVICE FOR TREATING OSTEOARTHRITIS AND CARTILAGE
DISEASE, DEFECTS, AND INJURIES IN THE HUMAN HIP
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present patent application claims priority to U.S. Provisional Patent Application Nos. 60/520,088 filed November 14, 2003 and 60/535,734 filed January 9, 2004.
The present patent application also claims priority to U.S. Patent Application Serial No.
10/257,126, filed October 8, 2002, entitled "Regulation of Genes Via Application of Specific and Selective Electrical and Electromagnetic Signals", which claims priority to PCT/LTSO1/05991 filed February 23, 2001, and U.S. Provisional Application No.
60/184,491 filed February 23, 2000, and U.S. Patent Application Serial Nos. 10/255,241, filed September 26, 2002, entitled "Regulation of Aggrecan Gene Expression with a Specific and Selective Electrical Signal", 10/267,708, filed October 9, 2002, entitled "Regulation of Type II Collagen Gene Expression with a Specific and Selective Electrical Signal", 10/457,167, filed June 9, 2003, entitled "Method and Apparatus for Treating Osteoarthritis, Cartilage Disease, Defects and Injuries in the Human Knee Joint," 10/461,188, filed June 13, 2003, entitled "Regulation of Matrix Metalloproteinase Gene Expression Using Specific and Selective Electrical and Electromagnetic Signals," and 10/603,226, filed June 25, 2003, entitled "Portable Electrotherapy Device for Treating Osteoarthritis and Other Diseases, Defects and Injuries of the Knee Joint."
The contents of all of these applications are hereby incorporated by reference in their entireties.
FIELD OF THE INVENTION
[0002] The present invention is directed to a method of determining the voltage and current output required for the application of specific and selective electric and electromagnetic signals to diseased articular cartilage"in the treatment of osteoarthritis, cartilage defects due to trauma or sports injuries, or as an adjunct with other therapies (e.g., cell transplantation, tissue-engineered scaffolds, growth factors, etc.) for treating cartilage defects in the human hip joint and a device for delivering such signals to a patient's hip.
BACKGROUND OF THE INVENTION
DISEASE, DEFECTS, AND INJURIES IN THE HUMAN HIP
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present patent application claims priority to U.S. Provisional Patent Application Nos. 60/520,088 filed November 14, 2003 and 60/535,734 filed January 9, 2004.
The present patent application also claims priority to U.S. Patent Application Serial No.
10/257,126, filed October 8, 2002, entitled "Regulation of Genes Via Application of Specific and Selective Electrical and Electromagnetic Signals", which claims priority to PCT/LTSO1/05991 filed February 23, 2001, and U.S. Provisional Application No.
60/184,491 filed February 23, 2000, and U.S. Patent Application Serial Nos. 10/255,241, filed September 26, 2002, entitled "Regulation of Aggrecan Gene Expression with a Specific and Selective Electrical Signal", 10/267,708, filed October 9, 2002, entitled "Regulation of Type II Collagen Gene Expression with a Specific and Selective Electrical Signal", 10/457,167, filed June 9, 2003, entitled "Method and Apparatus for Treating Osteoarthritis, Cartilage Disease, Defects and Injuries in the Human Knee Joint," 10/461,188, filed June 13, 2003, entitled "Regulation of Matrix Metalloproteinase Gene Expression Using Specific and Selective Electrical and Electromagnetic Signals," and 10/603,226, filed June 25, 2003, entitled "Portable Electrotherapy Device for Treating Osteoarthritis and Other Diseases, Defects and Injuries of the Knee Joint."
The contents of all of these applications are hereby incorporated by reference in their entireties.
FIELD OF THE INVENTION
[0002] The present invention is directed to a method of determining the voltage and current output required for the application of specific and selective electric and electromagnetic signals to diseased articular cartilage"in the treatment of osteoarthritis, cartilage defects due to trauma or sports injuries, or as an adjunct with other therapies (e.g., cell transplantation, tissue-engineered scaffolds, growth factors, etc.) for treating cartilage defects in the human hip joint and a device for delivering such signals to a patient's hip.
BACKGROUND OF THE INVENTION
[0003] The bioelectrical interactions and activity believed to be present in a variety of biological tissues and cells are one of the least understood of the physiological processes.
However, there has recently been much reseaxch into these interactions and activities related to the growth and repair of certain tissues and cells. In particular, there has been considerable interest in stimulation by electric and electromagnetic fields and their effect on the growth and repair of bone and cartilage. Scientists believe that such research might be useful in the development of new treatments for a variety of medical problems.
However, there has recently been much reseaxch into these interactions and activities related to the growth and repair of certain tissues and cells. In particular, there has been considerable interest in stimulation by electric and electromagnetic fields and their effect on the growth and repair of bone and cartilage. Scientists believe that such research might be useful in the development of new treatments for a variety of medical problems.
[0004] Osteoarthritis, also known as degenerative joint disease, is characterized by degeneration of articular cartilage as well as proliferation and remodeling of subchondral bone.
The usual symptoms are stiffiiess, limitation of motion, and pain.
Osteoarthritis is the most common form of arthritis, and prevalence rates increase markedly with age. It has been shown that elderly patients with self reported osteoarthritis visit doctors twice as frequently as their unaffected peers. Such patients also experience more days of restricted activity and bed confinement compared to others in their age group. In one study, the majority of symptomatic patients became significantly disabled during an 8-year follow-up period (Massardo et al., Anh Rheum Dis 48:893-897, 1989).
The usual symptoms are stiffiiess, limitation of motion, and pain.
Osteoarthritis is the most common form of arthritis, and prevalence rates increase markedly with age. It has been shown that elderly patients with self reported osteoarthritis visit doctors twice as frequently as their unaffected peers. Such patients also experience more days of restricted activity and bed confinement compared to others in their age group. In one study, the majority of symptomatic patients became significantly disabled during an 8-year follow-up period (Massardo et al., Anh Rheum Dis 48:893-897, 1989).
[0005] Nonsteroidal anti-inflammatory drugs (NSAIDs) remain the primary treatment modality for osteoarthritis. It is unknown whether the efficacy of NSAIDs is dependent upon their analgesic or anti-inflammatory properties or the slowing of degenerative processes in the cartilage. There is also a concern that NSAIDs may be deleterious to patients.
For example, NSAIDs display well-known toxic effects in the stomach, gastrointestinal tract, liver and kidney.
Moreover, aspirin inhibits proteoglycan synthesis and normal cartilaginous repair processes in animals. One study in humans also suggested that indomethacin might accelerate breakdown of hip cartilage. All adverse effects appear more commonly in the elderly-the very population most susceptible to osteoarthritis.
For example, NSAIDs display well-known toxic effects in the stomach, gastrointestinal tract, liver and kidney.
Moreover, aspirin inhibits proteoglycan synthesis and normal cartilaginous repair processes in animals. One study in humans also suggested that indomethacin might accelerate breakdown of hip cartilage. All adverse effects appear more commonly in the elderly-the very population most susceptible to osteoarthritis.
[0006] In the disease commonly known as osteoporosis, bone demineralizes and becomes abnormally rarefied. Bone comprises an organic component of cells and matrix as well as an inorganic or mineral component. The cells and matrix comprise a framework of collagenous fibers that is impregnated with the mineral component of calcium phosphate (85%) and calcium carbonate (10%) that imparts rigidity to bone. While osteoporosis is generally thought to afflict the elderly, certain types of osteoporosis may affect persons of all ages whose bones are not subject to functional stress. In such cases, patients may experience a significant loss of cortical and cancellous bone during prolonged periods of immobilization. Elderly patients are known to experience bone loss due to disuse when immobilized after fracture of a bone;
this may ultimately lead to a secondary fracture in an already osteoporotic skeleton.
Diminished bone density may lead to collapse of vertebrae, fractures of hips, lower arms, wrists and ankles, as well as incapacitating pains. Alternative non-surgical therapies for such diseases are needed.
this may ultimately lead to a secondary fracture in an already osteoporotic skeleton.
Diminished bone density may lead to collapse of vertebrae, fractures of hips, lower arms, wrists and ankles, as well as incapacitating pains. Alternative non-surgical therapies for such diseases are needed.
[0007] Pulsed electromagnetic fields (PEMFs) and capacitive coupling (CC) have been used widely to treat non-healing fractures and related problems in bone healing since approval by the Food and Drug Administration in 1979. The original basis for the trial of this form of therapy was the observation that physical stress on bone causes the appearance of tiny electric currents that, along with mechanical strain, were thought to be the mechanisms underlying transduction of the physical stress into a signal that promotes bone formation. Along with direct electric field stimulation that was successful in the treatment of nonunion bone fractures, noninvasive technologies using PEMF and CC (where the electrodes are placed on the skin in the treatment zone) were also found to be effective. PEMFs generate small, induced currents (Faraday currents) in the highly conductive extracellular fluid, while CC directly causes currents in the tissues; both PEMFs and CC thereby mimic endogenous electrical currents.
[0008] The endogenous electrical currents, originally thought to be due to phenomena occurring at the surface of crystals in the bone, have been shown to be due primarily to movement of fluid containing electrolytes in channels of the bone containing organic constituents with fixed negative charges, generating what are called "streaming 'potentials."
Studies of electrical phenomena in cartilage have demonstrated a mechanical-electrical transduction mechanism that resembles those described in bone, appearing when cartilage is mechanically compressed, causing movement of fluid and electrolytes over the surface of fixed negative charges in the proteoglycans and collagen in the cartilage matrix.
These streaming potentials apparently serve a purpose in cartilage similar to that in bone, and, along with mechanical strain, lead to signal transduction that is capable of stimulating chondrocyte synthesis of matrix components.
Studies of electrical phenomena in cartilage have demonstrated a mechanical-electrical transduction mechanism that resembles those described in bone, appearing when cartilage is mechanically compressed, causing movement of fluid and electrolytes over the surface of fixed negative charges in the proteoglycans and collagen in the cartilage matrix.
These streaming potentials apparently serve a purpose in cartilage similar to that in bone, and, along with mechanical strain, lead to signal transduction that is capable of stimulating chondrocyte synthesis of matrix components.
[0009] The main application of direct current, CC, and PEMFs has been in orthopaedics in the healing of nonunion bone fractures (Brighton et al. J Bone Joint Surg 1981;63:2-13;
Brighton and Pollack JBohe Joint Sung 1985;67:577-585; Bassett et al. Crit Rev Biomed Eng 1989;17:451-529; Bassett et al. JAm Med Assoc 1982;247:623-628). Clinical responses have been reportedly in avascular necrosis~~~~of hips in adults and Legg-Perthe's disease in children (Bassett et al. Clip Orthop 1989;246:172-176; Aaron et al. Clip Orthop 1989;249:209-218;
Harrison et al. J Pediatr Orthop 1984;4:579-584, 1984). It has also been shown that PEMFs (Mooney. Spine 1990;15:708-712) and CC (Goodwin et al. Spine 1999;24:1349-135) can significantly increase the success rate of lumbar fusions. There are also reports of augmentation of peripheral nerve regeneration and function and promotions of angiogenesis (Bassett.
Bioessays 1987;6:36-42). Patients with persistent rotator cuff tendonitis refractory to steroid injection and other conventional measures showed significant benefit compared with placebo treated patients (Binder et al. Lancet 1984;695-698). Finally, Brighton et al., have shown in rats the ability of an appropriate CC electric field to both prevent and reverse vertebral osteoporosis in the lumbar spine (Brighton et al. J Orthop Res 1988;6:676-684; Brighton et al. JBone Joint Surg 1989;71:228-236).
Brighton and Pollack JBohe Joint Sung 1985;67:577-585; Bassett et al. Crit Rev Biomed Eng 1989;17:451-529; Bassett et al. JAm Med Assoc 1982;247:623-628). Clinical responses have been reportedly in avascular necrosis~~~~of hips in adults and Legg-Perthe's disease in children (Bassett et al. Clip Orthop 1989;246:172-176; Aaron et al. Clip Orthop 1989;249:209-218;
Harrison et al. J Pediatr Orthop 1984;4:579-584, 1984). It has also been shown that PEMFs (Mooney. Spine 1990;15:708-712) and CC (Goodwin et al. Spine 1999;24:1349-135) can significantly increase the success rate of lumbar fusions. There are also reports of augmentation of peripheral nerve regeneration and function and promotions of angiogenesis (Bassett.
Bioessays 1987;6:36-42). Patients with persistent rotator cuff tendonitis refractory to steroid injection and other conventional measures showed significant benefit compared with placebo treated patients (Binder et al. Lancet 1984;695-698). Finally, Brighton et al., have shown in rats the ability of an appropriate CC electric field to both prevent and reverse vertebral osteoporosis in the lumbar spine (Brighton et al. J Orthop Res 1988;6:676-684; Brighton et al. JBone Joint Surg 1989;71:228-236).
[0010] More recently, research in this area has focused on the effects that stimulation has on tissues and cells. For example, it has been conjectured that direct currents do not penetrate cellular membranes and that control is achieved via extracellular matrix differentiation (Grodzinsky Crit Rev Biomed Eng 1983;9:133). In contrast to direct currents, it has been reported that PEMFs can penetrate cell membranes and either stimulate them or directly affect intracellular organelles. An examination of the effect of PEMFs on extracellular matrices and in vivo endochondral ossification found increased synthesis of cartilage molecules and maturation of bone trabeculae (Aaron et al. J Bone Miner Res 1998;4:227-233). More recently, it was reported (Lorich et al. Clip Orthop Related Res 1998;350:246-256) that signal transduction of a capacitively coupled electric signal is via voltage-gated calcium channels, leading to an increase in cytosolic calcium with a subsequent increase in activated (cytoskeletal) calinodulin.
[0011] Much research has been performed using tissue culture techniques in order to understand the mechanisms of response. In one study, it was found that electric fields increased [3H]thymidine incorporation into the DNA of chondrocytes, supporting the notion that Na~ and Ca+Z fluxes generated by electrical stimulation trigger DNA synthesis (Rodan et al. Science 1978;199:690-692). Studies have found changes in the second messenger, CAMP, and cytoskeletal rearrangements due to electrical perturbations (Ryaby et al.
Traps BRAGS 1986;6;
Jones et al. Traps. BRAGS 6:51, 1986; Brighton and Townsend J Ort7ZOp Res 1988;6:552-558).
Other studies have found effects on glycosaminoglycan, sulfation, hyaluronic acid, lysozyme activity and polypeptide sequences (Norton et al. J Orthop Res 1988;6:685-689;
Goodman et al. Proc Natl Acad Sci 1988;8'5:3928-3932).
Traps BRAGS 1986;6;
Jones et al. Traps. BRAGS 6:51, 1986; Brighton and Townsend J Ort7ZOp Res 1988;6:552-558).
Other studies have found effects on glycosaminoglycan, sulfation, hyaluronic acid, lysozyme activity and polypeptide sequences (Norton et al. J Orthop Res 1988;6:685-689;
Goodman et al. Proc Natl Acad Sci 1988;8'5:3928-3932).
[0012] It was reported irl'~'1 f96 by one of the present inventors that a cyclic, biaxial 0.17% mechanical strain produces a significant increase in TGF-(31 mRNA in cultured MC3T3-E1 bone cells (Zhuang et al. Biochem Biophys Res Cornmun 1996;229:449-453).
Several significant studies followed in 1997. In one study it was reported that the same cyclic, biaxial 0.17% mechanical strain produced a significant increase in PDGF-A mRNA in similar bone cells (Wang et al. Biochem Mol Biol Int 1997;43:339-346). It was also reported that a 60 kHz capacitively coupled electric field of 20 mV/cm produced a significant increase in TGF-[31 mRNA in similar bone cells (Zhuang et al. Biochem Biophys Res Comnaun 1997;237:225-229).
However, the effect such a field would have on other genes has not been reported in the literature.
Several significant studies followed in 1997. In one study it was reported that the same cyclic, biaxial 0.17% mechanical strain produced a significant increase in PDGF-A mRNA in similar bone cells (Wang et al. Biochem Mol Biol Int 1997;43:339-346). It was also reported that a 60 kHz capacitively coupled electric field of 20 mV/cm produced a significant increase in TGF-[31 mRNA in similar bone cells (Zhuang et al. Biochem Biophys Res Comnaun 1997;237:225-229).
However, the effect such a field would have on other genes has not been reported in the literature.
(0013] In the above-referenced parent patent application, entitled "Regulation of Genes Via Application of Specifzc and Selective Electrical and Electromagnetic Signals, " methods were disclosed for determining the specific and selective electrical and electromagnetic signals for use in creating specific and selective fields for regulating target genes of diseased or injured tissues.
The present invention builds upon the technique described therein by describing the method of determining the voltage and current output required, and the corresponding apparatus for delivering specific and selective electrical and electromagnetic signals to the human hip joints in patients afflicted with osteoarthritis and other cartilage defects, diseases and injuries.
SUMMARY OF THE INVENTION
The present invention builds upon the technique described therein by describing the method of determining the voltage and current output required, and the corresponding apparatus for delivering specific and selective electrical and electromagnetic signals to the human hip joints in patients afflicted with osteoarthritis and other cartilage defects, diseases and injuries.
SUMMARY OF THE INVENTION
(0014] The present invention related to treating osteoarthritis and other cartilage diseases, defects, and injuries in human hip joints via the application of specific and selective fields generated by specific and selective electric and/or electromagnetic signals.
The invention includes a method of determining the voltage and current of the signal to apply to electrodes or to a solenoid or to at least one coil applied to the hip for treatment.
The invention includes a method of determining the voltage and current of the signal to apply to electrodes or to a solenoid or to at least one coil applied to the hip for treatment.
[0015] More particularly, the invention relates to a method of treating diseased tissue in a human through the application of a specific and selective electric or electromagnetic field to diseased tissue in a human, including osteoarthritis and other cartilage diseases, defects and injuries in the hip, or used as an adjunct with other therapies (cell transplantation, tissue-engineered scaffolds, growth factors, etc.) in treating cartilage defects in the human hip. The method includes the steps of determining the voltage and current output that produces the desired 20 mV/cm electric field in the articular cartilage of the human hip joint, and other voltage and current values for other effective electric field amplitudes thought or known to be effective. The method includes constructing an anatomic model of the human hip joint and translating the anatomic model to an analytical model of the hip in which the dimensions for the tissues encountered from skin (anterior] tTirough fat and skm (posterior) are determined. Planar circuits were then constructed in which the various tissue conductivities, impedances and current flow were used in calculating the voltage and current required to be applied to surface electrodes placed anteriorly and posteriorly on the skin covering the hip in order to produce an electric field at 20 mV/cm in articular cartilage of the hip joint at a frequency of 60 kHz.
One knowledgeable in the field could perform the same analysis at other frequencies, adjust the tissue impedances to their values at the new frequency and obtain different values for the ranges of the electrical field and current density at any chosen frequency or set of frequencies.
One knowledgeable in the field could perform the same analysis at other frequencies, adjust the tissue impedances to their values at the new frequency and obtain different values for the ranges of the electrical field and current density at any chosen frequency or set of frequencies.
[0016] The invention also includes a method and a device for treating diseased tissue (such as osteoarthritis), defective or injured tissue in a human hip joint through the application of a specific and selective electric or electromagnetic field to the afflicted tissue in the human hip joint. Such a device in accordance with a capacitive coupling embodiment of the invention includes at least two electrodes adapted for application in the proximity of a patient's hip joint and a signal generator that generates electric signals for application to the electrodes so as to produce an electric field of amplitude of 20 mV/cm ~ 15% and a current density of 120 ~.A/cm2 ~ 15% within the synovium and articular cartilage of the patient's hip joint.
An inductive coupling embodiment of the invention includes a coils) or solenoid adapted and configured to receive the electric signals to produce these electric fields. Preferably, the signal generator provides one of a plurality of output electric signals with a voltage selected by a user in accordance with a size of the human hip joint. Larger hip joints receive signals of larger voltages.
An inductive coupling embodiment of the invention includes a coils) or solenoid adapted and configured to receive the electric signals to produce these electric fields. Preferably, the signal generator provides one of a plurality of output electric signals with a voltage selected by a user in accordance with a size of the human hip joint. Larger hip joints receive signals of larger voltages.
[0017] These and other aspects of the present invention will be elucidated in the following detailed description of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
BRIEF DESCRIPTION OF THE DRAWINGS
[0018] The present invention will be apparent from the following detailed description of the invention in conjunction with the accompanying drawings, of which:
[0019] Figure 1 illustrates an anatomic model of the human hip joint showing all the important tissues and structures through which the current passes between the anterior and posterior surface electrodes placed on skin.
[0020] Figure 2 illustrates an analytical model of the human hip joint from which size parameters are determined for each of the tissues and structures indicated.
[0021] Figure 3A illustrates a planar circuit model of the human hip joint showing circumferential flow of current through the fat layers (I3) plus leakage flow of current through the muscle and other soft tissue (I4), plus current flow across the hip joint (Ia) and the impedance (Z) compartments.
[0022] Figu~e-3B""illustrates 'a planar circuit showing in detail the current flow and impedances across the hip joint (ZTi).
[0023] Figure 4 illustrates schematically the three currents that were calculated in determining the output current and voltage required to produce a 20 mV/cm field ll1 the articular cartilage of the hip joint. The three currents are the circumferential current, the leakage current, and the current flowing through the hip j oint.
[0024] Figure S illustrates electrode placement on the skin that is required to produce the desired electric field in the hip joint.
DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
[0025] The invention will be described with reference to Figures 1-5 and Tables 1-3.
Those skilled in the art will appreciate that the description given herein with respect to these figures is for exemplary purposes only and is not intended in any way to limit the scope of the invention. All questions regarding the scope of the invention may be resolved by referring to the appended claims.
De anitiohs:
Those skilled in the art will appreciate that the description given herein with respect to these figures is for exemplary purposes only and is not intended in any way to limit the scope of the invention. All questions regarding the scope of the invention may be resolved by referring to the appended claims.
De anitiohs:
[0026] As used herein, the term "signal" is used to refer to a variety of signals including mechanical signals, ultrasound signals, electromagnetic signals, and electric signals outputted by a device.
[0027] As used herein, the term "field" refers to an electric field within a targeted tissue, whether it is a combined field or a pulsed electromagnetic field, or generated by direct current, capacitive coupling, or inductive coupling.
Dete~mihation o Irolta a and Current: .
Dete~mihation o Irolta a and Current: .
[0028] Previous studies by the present inventors have shown that a capacitively coupled field significantly increased the proliferation of bone cells grown in culture (Brighton, Pollaclc, et al, V. Orthop. Research, 3:331-340, 1985) and significantly increased the rate of healing in a rat fractured fibula model (Brighton, Pollack, et al, Clin. Orthop. And Related Research, 285:255-262, 1992). Also, the field distributions in the vertebral bodies of rats during capacitively coupled electrical stimulation have been determined (Carter, Vresilovic, Pollack, and Brighton, IEEE transactions on Biomedical Engineering, 36(-3): 333-3345,1989). In order to determine the required output voltage and current required to produce an equivalent electric field and current density in a human hip joint, the analytical model depicted in Figure 2 was developed in accordance with the invention for representing the typical human hip joint illustrated in Figure 1.
j ~s mown m rfigure i, fine typical human hip joint includes layers of cartilage and synovial fluid that is bounded by the acetabulum and the femoral head. In accordance with the invention, osteoarthritis, cartilage disease, defects and injuries in the hip joint is treated by the application of specific and selective electric fields via electrodes 10, 20 attached relative to the hip joint substantially as shown in Figure 1. A signal generator 30 provides the appropriate signals to the electrodes for generating the specific and selective electric fields. The specific and selective electric field needed to treat osteoarthritis, cartilage disease, defects and injuries in the hip joint is calculated in accordance with the invention using the analytical model of the hip joint depicted in Figure 2.
[0030] Figure 1 illustrates an anatomical model for use in determining the electric field amplitude and current density obtained in the cartilage space in a hip joint when electrodes 10, 20 are placed anteriorly and posteriorly, respectively, and a voltage is applied causing a current to flow through the body. In the analytical model of Figure 2, the following elements axe identified as indicated: electrodes 10, 20, skin 40, fat 50, muscle 60, bone (acetabulum) 70, cartilage and synovial fluid ~0, and femoral head 90. In an exemplary embodiment, the frequency of a sine wave voltage is taken to be 60 kHz; however, the methodology described herein can be applied to any frequency as long as the electrical properties of the tissues are chosen for those frequencies. It is desired to determine the voltage and the current to be applied to the electrodes 10, 20 in order to obtain in the cartilage of the hip joint a therapeutic electric field amplitude of 20 mV/cm in a preferred embodiment, and voltage and current values for other effective electric field amplitudes known to be effective.
[0031] It is clear from Figures 1 and 2 that patients of different sizes may require different applied voltages and currents to achieve the therapeutic electric field amplitudes.
Accordingly, the calculation in accordance with the invention will model the patient for four (4) different size classifications. The essential geometric model parameters for these four sizes along with the relevant electrical properties of all tissue types are shown below in Tables 1A and 1B
with reference to the distances illustrated in Figure 2. The electrodes 10, 20 are assumed to be 2"
x 2" square and the currents are calculated by considering the current flow through the patient's body for a 2" x 2" rectangle from one electrode to the other plus the circumferential flow of current through the fat layer plus the leakage current that flows through the muscle and other soft tissues outside of the 2" x 2" rectangle but excluding the circumferential current in the fat layer.
These currents are shown in Figures 3 and 4. The impedances of the tissue compartments through which the current I2 (Figure 3) flows are shown in Figure 3B. A line drawing showing patient electrode placement is presented in Figure 5. In Figure 5, the region in broken lines is _g_ modeled as a 2," x 2" rectangle 100 in which the body current is assumed to flow. Leakage currents as shown in Figures 3A and 4 include circumferential flow in the fat layer and body currents outside of the 2" x 2" rectangle 100. The current flow and impedance through region 100 are those shown in Figure 3B.
TABLE IA. Size Parameters for Four Patient Classifications Patieyat Classi acation Measurement Small Medium Large Extra-Large (m) (m) (m) (m) Electrode-to electrode distance0.1524 0.18 0.21 0.305 D* ' Fat layer thicl~ness F*) 0.00635 0.00762 0.0222 0.699 Fat layer width 0.051 0.051 0.051 0.051 Muscle (M3*) length 0.051 0.0635 0.0635 0.0635 Muscle (M3*) width 0.051 0.051 0.051 0.051 Muscle (M4*) length 0.0635 0.0762 0.0762 0.0762 Muscle (M4* width 0.0254 0.0254 0.0254 0.0254 Muscle (Mg*) length 0.0254 0.0254 0.0254 0.0254 Muscle (M8*) width 0.051 0.051 0.051 0.051 Cartilage junction length 0.08 0.08 0.08 0.08 Cartila a junction width 0.0127 0.0127 0.0127 0.0127 Femoral head radius (R*) 0.0254 0.0254 0.0254 0.0254 Acetabular thickness (B* 0.015 0.015 0.015 0.015 Acetabular width 0.04 0.04 0.04 0.04 *See Figure 2 TABLE 1B. Electrical Conductivities TISSUE CONDUCTIVITY
Fat 0.02 S/m Muscle 0.45 S/m Bone 0.01 S/m Cartila a 0.6 S/m Shin Admittance 3 x 10-3 S/cm2 [0032] The definitions of terms in Figures 2, 3A, 3B and 4 are shown below in Table 2.
Each impedance labeled in Figures 3 and 4 was calculated using the relationship:
1 ~ Length (Equatioh 1) a- Area Where Levcgth is the dimension of the tissue in the direction of the current flow, Area is the cross-sectional area of the tissue perpendicular to the direction of current flow, and 6 is the electrical conductivity.
TABLE 2. Definitions of dimensions and symbols showh in Figures 2 and 3 D = electrode to electrode distance F = fat layer thickness M = muscle:
M3 = distance (thickness) of muscle from posterior fat layer to posterior acetabulum M4 = distance (thickness) of muscle from posterior acetabulum to anterior acetabulum M8 = distance (thickness) of muscle from anterior acetabulum to anterior fat layer Z = impedance:
ZI = impedance of skin Z2 = impedance of fat Z3 = impedance of muscle posterior to the acetabulum Z4 = impedance of the muscle around the hip joint ZS = impedance of bone (acetabulum) zFH Z6 = impedance of bone (femoral head) Z7 = impedance of articular cartilage-synovium Z8 = impedance of muscle anterior to the acetabulum ZT,=impedance across the hip joint;
i.e., the combined impedance from Point A to Point B in Figure I = current:
Itot~ =
total current flowing from electrode to electrode IFH = current flowing through hip joint I4 = current flowing through muscle I6 = current flowing through femoral head I7 = current flowin throu h articular cartilage B = Bone (acetabulum) thickness C = cartilage-synovium~thicl~ness R = radius of femoral head J = current density (A/cm') E = electric field (V/cm) [0033] The impedances were then calculated using Equation l, the dimensions in Table 1A and the conductivities in Table 1B. Using standard lump circuit analysis for series/parallel impedances, the total current, h (Figure 3A) that must flow from the electrodes was calculated for each patient classification for a voltage applied to the electrodes. In addition, Ia, the current flow through the muscle-femur-cartilage-muscle layers; the current I3, the current flowing circumferentially through the fat layer and I4, the leakage currents, were also calculated. This enabled the calculation of the current through the cartilage, I~arritage~ ~d the current density, .IcarrilageW'om which the electric field amplitude in the cartilage, E~artilage~ could be computed from the equation:
~Icartilage - 6cartilage ~ ~' cartilage (E~uatiolZ 2~
where ,Jcartilage ~d ~' cartilage ar'e described above and 6cartilage is the electrical conductivity of the cartilage as shown in Table 1B. These results are summarized in Table 3A. From Table 3A, it is apparent that for an applied voltage of approximately 5 V peak-to-peak sine wave at 60 kHz, one obtains electric fields of 20 mV/cm ~ 3.5 mV/cm for the small, medium and large patient, but not for the extra-large patient. The extra-large patient requires a voltage that is approximately twice that required for the other three patient sizes.
TABLE 3A. Device Voltage and Current Required to Apply 20 mYlcm Electric Field to Cartilage in the Human Hip Patient Size Device Voltage Device Current Electrode Current 2" x 2" electrodeDensity Small 4.3 V _ 26.8 mA 1.04 mA/cm Medium 4.5 V _ 31.6 mA 1.23 mA/cm Large 5.7 V _ 32.0 mA 1.24 mA/cm Extra Large 10.2 V _ 52.1 mA 2.02 mA/cm ' [0034] It is now possible to calculate the device current to the 2" x 2"
electrodes 10, 20 in order to achieve a 20 mV/cm electric field amplitude in the cartilage. These values, and the approximate device voltages that achieve these device currents are shown below in Table 3B
along with the current and current density in the cartilage when the applied voltage is as shown for each patient size:
TABLE 3B. Cartilage Curreozt afzd Current Density Wheh a 20 m ~lcm Electric Field is Applied to the Cartilage of'tlze Human Hip Patient Size Cartila a Current Cartila a Current Densi Small 0.1 S mA 120 A/cma Medium 0.15 mA 120 ~A/cm2 Large 0.15 mA 120 ~.A/cm2 Extra Large 0.15 mA 127 A/cm2 [0035] It is noted that for extra-large patients, the current density value at the electrodes, 2.02 mA/cm2, is at the maximum value and should not be exceeded.
[0036] It is understood that patients with a specific size, i.e., electrode-to-electrode dimension, may have tissue compartment sizes and/or skin impedance values that differ from those modeled here. Therefore, devices that power the electrodes should have output variability /
to increase the peak-to-peak voltage to achieve the desired electrode current (density).
[0037] The current (or electric field) that flows through the cartilage of the hip when a voltage is applied to the electrodes on the skin is determined by the impedances shown in Figures 3A and 3B. For a given patient size, the dimensions of various tissue compartments (and therefore their impedances) can vary so that the current that actually flows through the cartilage could be higher or lower than the values shown for an applied device voltage as shown above. Taking reasonable variations in dimensions of the tissue compartments for each patient size, it may be determined that for a given device voltage, the cartilage current (and therefore the cartilage electric field) could differ by X15%. Therefore, in order to account for this variation, and to account for the variation of skin electrical impedance from patient to patient, the device should be designed to apply the device current value plus or minus 15% to the pair of 2" x 2"
electrodes 10, 20.
[0038] Thus, in accordance with the invention, the approximate size of the patient's hip is determined, and a signal is generated and applied to the electrodes that will generate the desired electric field with a voltage of 20 mV/cm~l5% and a current density of wA/cm2~15% within the synovium and articular cartilage for treatment of osteoarthritis in the hip, for example. Preferably, the signal generator includes a select control (Figure 1) that allows the operator to select the proper output based on the size of the patient's hip.
[0039] Although implementations of the invention have been described in detail above, those skilled in the art will readily appreciate that many additional modifications are possible without materially departing from the novel teachings and advantages of the invention. For example, those skilled in the art will appreciate that the techniques of the invention may be applied to capacitive and inductive coupling systems. In the case of capacitive coupling, the scaled~vo~ltagevarid~T'currerii~~are~appit~a to the hip region using two electrodes as illustrated in Figures 1 and 2. On the other hand, in the case of inductive coupling, the scaled voltage and current are applied to the hip region using a solenoid or coil(s). Any such modifications are intended to be included within the scope of the invention as defined in the following claims.
j ~s mown m rfigure i, fine typical human hip joint includes layers of cartilage and synovial fluid that is bounded by the acetabulum and the femoral head. In accordance with the invention, osteoarthritis, cartilage disease, defects and injuries in the hip joint is treated by the application of specific and selective electric fields via electrodes 10, 20 attached relative to the hip joint substantially as shown in Figure 1. A signal generator 30 provides the appropriate signals to the electrodes for generating the specific and selective electric fields. The specific and selective electric field needed to treat osteoarthritis, cartilage disease, defects and injuries in the hip joint is calculated in accordance with the invention using the analytical model of the hip joint depicted in Figure 2.
[0030] Figure 1 illustrates an anatomical model for use in determining the electric field amplitude and current density obtained in the cartilage space in a hip joint when electrodes 10, 20 are placed anteriorly and posteriorly, respectively, and a voltage is applied causing a current to flow through the body. In the analytical model of Figure 2, the following elements axe identified as indicated: electrodes 10, 20, skin 40, fat 50, muscle 60, bone (acetabulum) 70, cartilage and synovial fluid ~0, and femoral head 90. In an exemplary embodiment, the frequency of a sine wave voltage is taken to be 60 kHz; however, the methodology described herein can be applied to any frequency as long as the electrical properties of the tissues are chosen for those frequencies. It is desired to determine the voltage and the current to be applied to the electrodes 10, 20 in order to obtain in the cartilage of the hip joint a therapeutic electric field amplitude of 20 mV/cm in a preferred embodiment, and voltage and current values for other effective electric field amplitudes known to be effective.
[0031] It is clear from Figures 1 and 2 that patients of different sizes may require different applied voltages and currents to achieve the therapeutic electric field amplitudes.
Accordingly, the calculation in accordance with the invention will model the patient for four (4) different size classifications. The essential geometric model parameters for these four sizes along with the relevant electrical properties of all tissue types are shown below in Tables 1A and 1B
with reference to the distances illustrated in Figure 2. The electrodes 10, 20 are assumed to be 2"
x 2" square and the currents are calculated by considering the current flow through the patient's body for a 2" x 2" rectangle from one electrode to the other plus the circumferential flow of current through the fat layer plus the leakage current that flows through the muscle and other soft tissues outside of the 2" x 2" rectangle but excluding the circumferential current in the fat layer.
These currents are shown in Figures 3 and 4. The impedances of the tissue compartments through which the current I2 (Figure 3) flows are shown in Figure 3B. A line drawing showing patient electrode placement is presented in Figure 5. In Figure 5, the region in broken lines is _g_ modeled as a 2," x 2" rectangle 100 in which the body current is assumed to flow. Leakage currents as shown in Figures 3A and 4 include circumferential flow in the fat layer and body currents outside of the 2" x 2" rectangle 100. The current flow and impedance through region 100 are those shown in Figure 3B.
TABLE IA. Size Parameters for Four Patient Classifications Patieyat Classi acation Measurement Small Medium Large Extra-Large (m) (m) (m) (m) Electrode-to electrode distance0.1524 0.18 0.21 0.305 D* ' Fat layer thicl~ness F*) 0.00635 0.00762 0.0222 0.699 Fat layer width 0.051 0.051 0.051 0.051 Muscle (M3*) length 0.051 0.0635 0.0635 0.0635 Muscle (M3*) width 0.051 0.051 0.051 0.051 Muscle (M4*) length 0.0635 0.0762 0.0762 0.0762 Muscle (M4* width 0.0254 0.0254 0.0254 0.0254 Muscle (Mg*) length 0.0254 0.0254 0.0254 0.0254 Muscle (M8*) width 0.051 0.051 0.051 0.051 Cartilage junction length 0.08 0.08 0.08 0.08 Cartila a junction width 0.0127 0.0127 0.0127 0.0127 Femoral head radius (R*) 0.0254 0.0254 0.0254 0.0254 Acetabular thickness (B* 0.015 0.015 0.015 0.015 Acetabular width 0.04 0.04 0.04 0.04 *See Figure 2 TABLE 1B. Electrical Conductivities TISSUE CONDUCTIVITY
Fat 0.02 S/m Muscle 0.45 S/m Bone 0.01 S/m Cartila a 0.6 S/m Shin Admittance 3 x 10-3 S/cm2 [0032] The definitions of terms in Figures 2, 3A, 3B and 4 are shown below in Table 2.
Each impedance labeled in Figures 3 and 4 was calculated using the relationship:
1 ~ Length (Equatioh 1) a- Area Where Levcgth is the dimension of the tissue in the direction of the current flow, Area is the cross-sectional area of the tissue perpendicular to the direction of current flow, and 6 is the electrical conductivity.
TABLE 2. Definitions of dimensions and symbols showh in Figures 2 and 3 D = electrode to electrode distance F = fat layer thickness M = muscle:
M3 = distance (thickness) of muscle from posterior fat layer to posterior acetabulum M4 = distance (thickness) of muscle from posterior acetabulum to anterior acetabulum M8 = distance (thickness) of muscle from anterior acetabulum to anterior fat layer Z = impedance:
ZI = impedance of skin Z2 = impedance of fat Z3 = impedance of muscle posterior to the acetabulum Z4 = impedance of the muscle around the hip joint ZS = impedance of bone (acetabulum) zFH Z6 = impedance of bone (femoral head) Z7 = impedance of articular cartilage-synovium Z8 = impedance of muscle anterior to the acetabulum ZT,=impedance across the hip joint;
i.e., the combined impedance from Point A to Point B in Figure I = current:
Itot~ =
total current flowing from electrode to electrode IFH = current flowing through hip joint I4 = current flowing through muscle I6 = current flowing through femoral head I7 = current flowin throu h articular cartilage B = Bone (acetabulum) thickness C = cartilage-synovium~thicl~ness R = radius of femoral head J = current density (A/cm') E = electric field (V/cm) [0033] The impedances were then calculated using Equation l, the dimensions in Table 1A and the conductivities in Table 1B. Using standard lump circuit analysis for series/parallel impedances, the total current, h (Figure 3A) that must flow from the electrodes was calculated for each patient classification for a voltage applied to the electrodes. In addition, Ia, the current flow through the muscle-femur-cartilage-muscle layers; the current I3, the current flowing circumferentially through the fat layer and I4, the leakage currents, were also calculated. This enabled the calculation of the current through the cartilage, I~arritage~ ~d the current density, .IcarrilageW'om which the electric field amplitude in the cartilage, E~artilage~ could be computed from the equation:
~Icartilage - 6cartilage ~ ~' cartilage (E~uatiolZ 2~
where ,Jcartilage ~d ~' cartilage ar'e described above and 6cartilage is the electrical conductivity of the cartilage as shown in Table 1B. These results are summarized in Table 3A. From Table 3A, it is apparent that for an applied voltage of approximately 5 V peak-to-peak sine wave at 60 kHz, one obtains electric fields of 20 mV/cm ~ 3.5 mV/cm for the small, medium and large patient, but not for the extra-large patient. The extra-large patient requires a voltage that is approximately twice that required for the other three patient sizes.
TABLE 3A. Device Voltage and Current Required to Apply 20 mYlcm Electric Field to Cartilage in the Human Hip Patient Size Device Voltage Device Current Electrode Current 2" x 2" electrodeDensity Small 4.3 V _ 26.8 mA 1.04 mA/cm Medium 4.5 V _ 31.6 mA 1.23 mA/cm Large 5.7 V _ 32.0 mA 1.24 mA/cm Extra Large 10.2 V _ 52.1 mA 2.02 mA/cm ' [0034] It is now possible to calculate the device current to the 2" x 2"
electrodes 10, 20 in order to achieve a 20 mV/cm electric field amplitude in the cartilage. These values, and the approximate device voltages that achieve these device currents are shown below in Table 3B
along with the current and current density in the cartilage when the applied voltage is as shown for each patient size:
TABLE 3B. Cartilage Curreozt afzd Current Density Wheh a 20 m ~lcm Electric Field is Applied to the Cartilage of'tlze Human Hip Patient Size Cartila a Current Cartila a Current Densi Small 0.1 S mA 120 A/cma Medium 0.15 mA 120 ~A/cm2 Large 0.15 mA 120 ~.A/cm2 Extra Large 0.15 mA 127 A/cm2 [0035] It is noted that for extra-large patients, the current density value at the electrodes, 2.02 mA/cm2, is at the maximum value and should not be exceeded.
[0036] It is understood that patients with a specific size, i.e., electrode-to-electrode dimension, may have tissue compartment sizes and/or skin impedance values that differ from those modeled here. Therefore, devices that power the electrodes should have output variability /
to increase the peak-to-peak voltage to achieve the desired electrode current (density).
[0037] The current (or electric field) that flows through the cartilage of the hip when a voltage is applied to the electrodes on the skin is determined by the impedances shown in Figures 3A and 3B. For a given patient size, the dimensions of various tissue compartments (and therefore their impedances) can vary so that the current that actually flows through the cartilage could be higher or lower than the values shown for an applied device voltage as shown above. Taking reasonable variations in dimensions of the tissue compartments for each patient size, it may be determined that for a given device voltage, the cartilage current (and therefore the cartilage electric field) could differ by X15%. Therefore, in order to account for this variation, and to account for the variation of skin electrical impedance from patient to patient, the device should be designed to apply the device current value plus or minus 15% to the pair of 2" x 2"
electrodes 10, 20.
[0038] Thus, in accordance with the invention, the approximate size of the patient's hip is determined, and a signal is generated and applied to the electrodes that will generate the desired electric field with a voltage of 20 mV/cm~l5% and a current density of wA/cm2~15% within the synovium and articular cartilage for treatment of osteoarthritis in the hip, for example. Preferably, the signal generator includes a select control (Figure 1) that allows the operator to select the proper output based on the size of the patient's hip.
[0039] Although implementations of the invention have been described in detail above, those skilled in the art will readily appreciate that many additional modifications are possible without materially departing from the novel teachings and advantages of the invention. For example, those skilled in the art will appreciate that the techniques of the invention may be applied to capacitive and inductive coupling systems. In the case of capacitive coupling, the scaled~vo~ltagevarid~T'currerii~~are~appit~a to the hip region using two electrodes as illustrated in Figures 1 and 2. On the other hand, in the case of inductive coupling, the scaled voltage and current are applied to the hip region using a solenoid or coil(s). Any such modifications are intended to be included within the scope of the invention as defined in the following claims.
Claims (23)
1. A method of treating disease tissue in a human through the application of a specific and selective electric or electromagnetic field to the disease tissue in the human, comprising the steps of:
a. Determining the voltage and current output that produces a 20 mV/cm electric field in the diseased tissue of the human;
b. Constructing an anatomic model of human diseased tissue showing all the pertinent tissues and structures through which the current passes between the skin overlying one side of the diseased tissue through the skin on the opposite side of the diseased tissue;
c. Constructing an analytic model of the diseased tissue from which size parameters are determined for each of the tissues and structures through which the current passes between the anterior and posterior skin surfaces enclosing the diseased tissue;
d. Constructing a planar circuit model of the diseased tissue giving the impedance and current flow in detail of all the structures and tissues through which the current must flow to achieve a 20 mV/cm electric field in the diseased tissue;
e. Computing the electric field amplitude (20 mV/cm) in the diseased tissue as equal to the targeted diseased tissue current density divided by the targeted diseased tissue conductivity; and f. Applying the computed voltage and current to the diseased tissue of the human.
a. Determining the voltage and current output that produces a 20 mV/cm electric field in the diseased tissue of the human;
b. Constructing an anatomic model of human diseased tissue showing all the pertinent tissues and structures through which the current passes between the skin overlying one side of the diseased tissue through the skin on the opposite side of the diseased tissue;
c. Constructing an analytic model of the diseased tissue from which size parameters are determined for each of the tissues and structures through which the current passes between the anterior and posterior skin surfaces enclosing the diseased tissue;
d. Constructing a planar circuit model of the diseased tissue giving the impedance and current flow in detail of all the structures and tissues through which the current must flow to achieve a 20 mV/cm electric field in the diseased tissue;
e. Computing the electric field amplitude (20 mV/cm) in the diseased tissue as equal to the targeted diseased tissue current density divided by the targeted diseased tissue conductivity; and f. Applying the computed voltage and current to the diseased tissue of the human.
2. The method of claim 1 wherein the computed voltage and current applying step comprises the step of applying the computed voltage and current to the human using two electrodes in the case of capacitive coupling.
3. The method of claim 1 wherein the computed voltage and current applying step comprises the step of applying the computed voltage and current to the human using a solenoid or coil(s) in the case of inductive coupling.
4. The method of claim 1 wherein the voltage and current output determining step comprises the step of determining the voltage and current output that produces a 20 mV/cm electric field in the tissues of the diseased human hip.
5. The method of claim 4 wherein the anatomic model constructing step comprises the step of constructing an anatomic model of the human hip.
6. The method of claim 5 wherein the step of constructing an anatomic model of the diseased tissue comprises the step of constructing an analytic model of the diseased human hip from which size parameters are determined for each of the tissues and structures through which the current passes between anterior and posterior skin surfaces enclosing the human hip.
7. The method of claim 6 wherein the step of constructing the planar circuit model comprises the step of constructing a planar circuit model of the human hip in order to determine the circumferential flow of current through a fat layer, a leakage flow of current through muscle and other soft tissue, and current flow across and through the human hip.
8. The method of claim 7 wherein the step of constructing the planar circuit model comprises the step of constructing a planar circuit model of the human hip giving the impedance and current flow of all the tissues and structures through which the current must flow to achieve a 20 mV/cm electric field in the human hip.
9. The method of claim 8 wherein the step of computing the electric field amplitude comprises the set of computing the desired electric field amplitude (20 mV/cm) in the diseased human hip as equal to the current density in the tissues of the hip divided by the conductivity of the tissues in the hip.
10. The method of claim 1 wherein the computed voltage and current are applied to a diseased human hip.
11. A device for treating diseased tissue in the human hip joint through the application of a specific and selective electric or electromagnetic field to the diseased or injured tissue in the human hip joint comprising:
a. one of (a) at least two electrodes, in the case of capacitive coupling, adapted for application in the proximity of a patient's hip joint; and (b) a solenoid or at least one coil, in the case of inductive coupling, adapted for application in the proximity of a patient's hip joint; and b. a signal generator that generates electric signals for application to the electrodes, the solenoid, or at least one coil so as to produce an electric field of approximately 20 mV/cm ~ 15% and a current density range of approximately 120 µA/cm2 ~ 15% within the synovium and articular cartilage of the patient's hip joint.
a. one of (a) at least two electrodes, in the case of capacitive coupling, adapted for application in the proximity of a patient's hip joint; and (b) a solenoid or at least one coil, in the case of inductive coupling, adapted for application in the proximity of a patient's hip joint; and b. a signal generator that generates electric signals for application to the electrodes, the solenoid, or at least one coil so as to produce an electric field of approximately 20 mV/cm ~ 15% and a current density range of approximately 120 µA/cm2 ~ 15% within the synovium and articular cartilage of the patient's hip joint.
12. A device for treating osteoarthritis, cartilage defects due to trauma or sports injury, or used as an adjunct with other therapies for treating cartilage defects in a human hip joint through the application of specific and selective electric or electromagnetic field to the afflicted tissue in the human hip joint, comprising:
a. one of (a) at least two electrodes on the surface of the skin and (b) a solenoid or at least one coil located external to the skin adapted for application in the proximity of a patient's hip joint; and b. a signal generator that generates electric signals for application to the electrodes, the solenoid, or at least one coil so as to produce an electric field of approximately 20 mV/cm ~ 15% and a current density range of approximately 120 µA/cm2 ~ 15% within the synovium and articular cartilage of the patient's hip joint.
a. one of (a) at least two electrodes on the surface of the skin and (b) a solenoid or at least one coil located external to the skin adapted for application in the proximity of a patient's hip joint; and b. a signal generator that generates electric signals for application to the electrodes, the solenoid, or at least one coil so as to produce an electric field of approximately 20 mV/cm ~ 15% and a current density range of approximately 120 µA/cm2 ~ 15% within the synovium and articular cartilage of the patient's hip joint.
13. A device as in claim 12, wherein the signal generator provides one of the plurality of output electric signals in accordance with a size of the human hip joint and its surrounding soft tissue and skin.
14. A device as in claim 13, wherein one of the plurality of output electrical signals of the signal generator for a 60 kHz frequency has a voltage of approximately 4.3 V p-p ~ 10%
for a small size hip joint.
for a small size hip joint.
15. A device as in claim 13, wherein one of the plurality of output electrical signals of the signal generator for a 60 kHz frequency has a voltage of approximately 4.5 V p-p ~ 10%
for a medium sized hip joint.
for a medium sized hip joint.
16. A device as in claim 13, wherein one of the plurality of output electrical signals of the signal generator for a 60 kHz frequency has a voltage of approximately 5.7 V p-p ~ 10%
for a large sized hip joint.
for a large sized hip joint.
17. A device as in claim 13, wherein one of the plurality of output electrical signals of the signal generator for a 60 kHz frequency has a voltage of approximately 10.2 V
p-p ~
10% for a extra large sized hip joint.
p-p ~
10% for a extra large sized hip joint.
18. A method of treating osteoarthritis in a human knee joint through the application of a specific and selective electric or electromagnetic field to the diseased tissue in the human knee joint, comprising the steps of:
converting electric potential into an electric signal that when applied to one of (a) at least two electrodes on the surface of the skin and (b) a solenoid or at least one coil located external to the skin adapted for application in the proximity of a patient's hip joint, an electric field of not less than approximately 20 mV/cm ~ 15% is produced and a current density of not less than approximately 120 µA/cm2 ~
15% is produced within the synovium and articular cartilage of the patient's hip joint; and applying the electric signal to the at least two electrodes, solenoid or coil so as to produce the electric field within the synovium and articular cartilage of the patient's hip joint.
converting electric potential into an electric signal that when applied to one of (a) at least two electrodes on the surface of the skin and (b) a solenoid or at least one coil located external to the skin adapted for application in the proximity of a patient's hip joint, an electric field of not less than approximately 20 mV/cm ~ 15% is produced and a current density of not less than approximately 120 µA/cm2 ~
15% is produced within the synovium and articular cartilage of the patient's hip joint; and applying the electric signal to the at least two electrodes, solenoid or coil so as to produce the electric field within the synovium and articular cartilage of the patient's hip joint.
19. A method as in claim 18, comprising the additional step of selecting one of a plurality of output electric signals with a voltage in accordance with a size of the human hip joint.
20. A method as in claim 19, wherein the selecting step comprises the step of selecting an electrical signal having a voltage of approximately 4.3 V p-p ~ 10% for a small size hip joint.
21. A method as in claim 19, wherein the selecting step comprises the step of selecting an electrical signal having a voltage of approximately 4.5 V p-p ~ 10% for a medium sized hip joint.
22. A method as in claim 19, wherein the selecting step comprises the step of selecting an electrical signal having a voltage of approximately 5.7 V p-p ~ 10% for a large sized hip joint.
23. A method as in claim 19, wherein the selecting step comprises the step of selecting an electrical signal having a voltage of approximately 10.2 V p-p ~ 10% for a extra large sized hip joint.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52008803P | 2003-11-14 | 2003-11-14 | |
US60/520,088 | 2003-11-14 | ||
US53573404P | 2004-01-09 | 2004-01-09 | |
US60/535,734 | 2004-01-09 | ||
PCT/US2004/037926 WO2005049132A1 (en) | 2003-11-14 | 2004-11-12 | Method and device for treating osteoarthritis and cartilage disease, defects, and injuries in the human hip |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2545860A1 true CA2545860A1 (en) | 2005-06-02 |
Family
ID=34623117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002545860A Abandoned CA2545860A1 (en) | 2003-11-14 | 2004-11-12 | Device for treating osteoarthritis and cartilage disease, defects, and injuries in the human hip |
Country Status (11)
Country | Link |
---|---|
US (2) | US20090062885A1 (en) |
EP (1) | EP1689487A4 (en) |
JP (1) | JP2007511289A (en) |
CN (1) | CN1893999A (en) |
AU (1) | AU2004291111A1 (en) |
CA (1) | CA2545860A1 (en) |
IL (1) | IL175619A0 (en) |
MX (1) | MXPA06005358A (en) |
NO (1) | NO20062787L (en) |
NZ (1) | NZ547198A (en) |
WO (1) | WO2005049132A1 (en) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7981611B2 (en) * | 2000-02-23 | 2011-07-19 | The Trustees Of The University Of Pennsylvania | Regulation of fibroblastic growth factor-2 (FGF-2) gene expression in living cells with the application of specific and selective electric and electromagnetic fields |
US7022506B2 (en) * | 2000-02-23 | 2006-04-04 | The Trustees Of The University Of Pennsylvania | Method and device for treating osteoarthritis, cartilage disease, defects and injuries in the human knee |
US7429471B2 (en) * | 2000-02-23 | 2008-09-30 | The Trustees Of The University Of Pennsylvania | Regulation of matrix metalloproteinase gene expression using specific and selective electrical and electromagnetic signals |
US8313908B2 (en) | 2000-02-23 | 2012-11-20 | The Trustees Of The University Of Pennsylvania | Regulation of stem cell gene production with specific and selective electric and electromagnetic fields |
US7465566B2 (en) | 2000-02-23 | 2008-12-16 | The Trustees Of The University Of Pennsylvania | Regulation of genes via application of specific and selective electrical and electromagnetic signals |
US7374916B2 (en) | 2000-02-23 | 2008-05-20 | The Trustees Of The University Of Pennsylvania | Regulation of aggrecan gene expression using specific and selective electrical and electromagnetic signals |
US7465546B2 (en) * | 2000-02-23 | 2008-12-16 | The Trustees Of The University Of Pennsylvania | Regulation of transforming growth factor-beta (TGF-β) gene expression in living cells via the application of specific and selective electric and electromagnetic fields |
US9440089B2 (en) | 2003-12-05 | 2016-09-13 | Rio Grande Neurosciences, Inc. | Apparatus and method for electromagnetic treatment of neurological injury or condition caused by a stroke |
US9433797B2 (en) | 2003-12-05 | 2016-09-06 | Rio Grande Neurosciences, Inc. | Apparatus and method for electromagnetic treatment of neurodegenerative conditions |
US10350428B2 (en) | 2014-11-04 | 2019-07-16 | Endonovo Therapetics, Inc. | Method and apparatus for electromagnetic treatment of living systems |
US9415233B2 (en) | 2003-12-05 | 2016-08-16 | Rio Grande Neurosciences, Inc. | Apparatus and method for electromagnetic treatment of neurological pain |
US8961385B2 (en) | 2003-12-05 | 2015-02-24 | Ivivi Health Sciences, Llc | Devices and method for treatment of degenerative joint diseases with electromagnetic fields |
US7744524B2 (en) * | 2003-12-05 | 2010-06-29 | Ivivi Health Sciences, Llc | Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules |
US20110112352A1 (en) * | 2003-12-05 | 2011-05-12 | Pilla Arthur A | Apparatus and method for electromagnetic treatment |
US20130218235A9 (en) * | 2005-03-07 | 2013-08-22 | Arthur A. Pilla | Excessive fibrous capsule formation and capsular contracture apparatus and method for using same |
US9656096B2 (en) | 2003-12-05 | 2017-05-23 | Rio Grande Neurosciences, Inc. | Method and apparatus for electromagnetic enhancement of biochemical signaling pathways for therapeutics and prophylaxis in plants, animals and humans |
JP4801802B2 (en) * | 2004-01-12 | 2011-10-26 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | Systems and methods for upregulating bone morphogenetic protein (BMP) gene expression in bone cells via application of electric fields generated by specific selective electrical and electromagnetic signals |
US8454543B2 (en) | 2004-03-10 | 2013-06-04 | Vision Quest Industries Incorporated | Electrodes for orthotic device |
US8936560B2 (en) | 2004-03-10 | 2015-01-20 | Vision Quest Industries Incorporated | Bracing and electrostimulation for arthritis |
US8070703B2 (en) * | 2004-03-10 | 2011-12-06 | Vision Quest Industries Incorporated | Electrically stimulating orthotic device and segmented liner |
MXPA06012077A (en) | 2004-04-19 | 2007-04-23 | Ivivi Technologies Inc | Electromagnetic treatment apparatus and method. |
US8082038B2 (en) * | 2004-07-09 | 2011-12-20 | Ebi, Llc | Method for treating degenerative disc disease using noninvasive capacitively coupled electrical stimulation device |
US7473678B2 (en) | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
KR20080084808A (en) * | 2005-11-17 | 2008-09-19 | 바이오미메틱 세라퓨틱스, 인크. | Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix |
US8078282B2 (en) * | 2006-02-01 | 2011-12-13 | Warsaw Orthopedic, Inc | Implantable tissue growth stimulator |
EP2311505B1 (en) * | 2006-02-09 | 2013-11-06 | BioMimetic Therapeutics, LLC | Compositions and methods for treating bone |
US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
AU2007269712B2 (en) | 2006-06-30 | 2013-02-07 | Biomimetic Therapeutics, Llc | PDGF-biomatrix compositions and methods for treating rotator cuff injuries |
US20090018613A1 (en) * | 2006-08-02 | 2009-01-15 | Genestim, Llc | Regulation of vascular endothelial growth factor (vegf) gene expression in tissue via the application of electric and/or electromagnetic fields |
EP2462895B1 (en) | 2006-11-03 | 2016-11-02 | BioMimetic Therapeutics, LLC | Compositions and methods for arthrodetic procedures |
US8768454B2 (en) * | 2007-05-03 | 2014-07-01 | Orthocor Medical, Inc. | Electromagnetic thermal therapy |
US9968797B2 (en) | 2007-05-03 | 2018-05-15 | Orthocor Medical, Inc. | Electromagnetic thermal therapy |
US7783348B2 (en) * | 2007-05-03 | 2010-08-24 | Orthocor Medical, Inc. | Stimulation device for treating osteoarthritis |
EP2254660A1 (en) * | 2008-01-29 | 2010-12-01 | Cardiac Pacemakers, Inc. | Configurable intermittent pacing therapy |
CN102014977B (en) | 2008-02-07 | 2015-09-02 | 生物模拟治疗有限责任公司 | For compositions and the method for Distraction Osteogenesis |
MX2011002555A (en) | 2008-09-09 | 2011-08-03 | Biomimetic Therapeutics Inc | Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries. |
US20100099942A1 (en) * | 2008-10-20 | 2010-04-22 | Lucas Portelli | Method and apparatus for electromagnetic human and animal immune stimulation and/or repair systems activation |
US20100324626A1 (en) * | 2009-06-23 | 2010-12-23 | Management Technologies, Inc. | Electrotherapy Stimilator for Osteoarthritis |
US8827886B2 (en) | 2009-09-14 | 2014-09-09 | Minnesota Medical Physics Llc | Thermally assisted pulsed electro-magnetic field stimulation device and method for treatment of osteoarthritis |
US8460167B2 (en) | 2009-09-14 | 2013-06-11 | Minnesota Medical Physics Llc | Thermally assisted pulsed electro-magnetic field stimulation device and method for treatment of osteoarthritis |
US8932196B2 (en) | 2009-09-14 | 2015-01-13 | Minnesota Medical Physics Llc | Thermally assisted pulsed electro-magnetic field stimulation device and method for treatment of osteoarthritis |
AU2011217784B2 (en) | 2010-02-22 | 2014-10-09 | Biomimetic Therapeutics, Llc. | Platelet-derived growth factor compositions and methods for the treatment of tendinopathies |
CA2813036A1 (en) | 2010-10-01 | 2012-04-05 | Ivivi Health Sciences, Llc | Method and apparatus for electromagnetic treatment of head, cerebral and neural injury in animals and humans |
US8972019B2 (en) | 2011-01-25 | 2015-03-03 | Kenneth L. Willeford | Method and device for treating osteoarthritis noninvasively |
US20120191018A1 (en) * | 2011-01-25 | 2012-07-26 | Willeford Kenneth L | Method and device for treating osteoarthritis noninvasively |
CA2842852C (en) | 2011-07-27 | 2020-07-14 | Vision Quest Industries Incorporated Dba Vq Orthocare | Electrostimulation system |
US8343027B1 (en) | 2012-01-30 | 2013-01-01 | Ivivi Health Sciences, Llc | Methods and devices for providing electromagnetic treatment in the presence of a metal-containing implant |
US10046172B2 (en) * | 2013-03-15 | 2018-08-14 | Nativis, Inc. | Controller and flexible coils for administering therapy, such as for cancer therapy |
US9044611B2 (en) * | 2013-03-15 | 2015-06-02 | The Regents Of The University Of California | Systems and methods for selectively migrating cells using electric fields |
WO2015161063A1 (en) | 2014-04-16 | 2015-10-22 | Iviv Health Sciences, Llc | A two-part pulsed electromagnetic field applicator for application of therapeutic energy |
US9770591B2 (en) | 2015-12-29 | 2017-09-26 | Rainbow Medical Ltd. | Disc therapy |
US11484706B2 (en) | 2015-12-29 | 2022-11-01 | Discure Technologies Ltd | Disc therapy |
WO2018089795A1 (en) | 2016-11-10 | 2018-05-17 | Qoravita LLC | System and method for applying a low frequency magnetic field to biological tissues |
CL2017003462A1 (en) | 2017-12-28 | 2019-10-18 | Univ Pontificia Catolica Chile | Recording device of the vascular response of the human spinal cord triggered by a supra-sensitive stimulus using near-infrared functional spectroscopy |
CN110090358A (en) * | 2018-01-29 | 2019-08-06 | 邦尼塔斯研究中心有限公司 | Blood magnetic stimulating device |
CN108031002B (en) * | 2018-02-08 | 2021-06-29 | 中国医科大学附属盛京医院 | Electrical stimulation apparatus for promoting regeneration of autograft fat flap |
DE102018112297B4 (en) * | 2018-05-23 | 2022-06-30 | Universität Rostock | Implant arrangement for electrical stimulation of cartilage tissue |
US11298530B1 (en) | 2021-05-03 | 2022-04-12 | Discure Technologies Ltd. | Synergistic therapies for intervertebral disc degeneration |
US11344721B1 (en) * | 2021-08-16 | 2022-05-31 | Rainbow Medical Ltd. | Cartilage treatment |
US11413455B1 (en) | 2022-02-08 | 2022-08-16 | Rainbow Medical Ltd. | Electrical treatment of Alzheimer's disease |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2432493C2 (en) * | 1974-07-04 | 1985-01-03 | Werner Dipl.-Ing. 8000 München Kraus | Solenoid coil for an electromagnetic therapy device |
US4442846A (en) * | 1981-11-10 | 1984-04-17 | University Of Pennsylvania | Distributed port bone-piercing cathode for electrically stimulated osteogenesis |
US4430999A (en) * | 1981-11-10 | 1984-02-14 | Trustees Of The University Of Pennsylvania | Osteogenesis stimulating cathode assembly for use with an internal fixation device |
US4506674A (en) * | 1981-11-10 | 1985-03-26 | Trustees Of The University Of Pennsylvania | Method of stimulating osteogenesis with distributed port cathode |
US4509520A (en) * | 1982-02-22 | 1985-04-09 | Biolectron, Inc. | Electrical stimulating apparatus |
US4459988A (en) * | 1982-02-22 | 1984-07-17 | Biolectron, Inc. | Electrical stimulating apparatus |
US4549547A (en) * | 1982-07-27 | 1985-10-29 | Trustees Of The University Of Pennsylvania | Implantable bone growth stimulator |
US4467808A (en) * | 1982-09-17 | 1984-08-28 | Biolectron, Inc. | Method for preventing and treating osteoporosis in a living body by using electrical stimulation non-invasively |
US4467809A (en) * | 1982-09-17 | 1984-08-28 | Biolectron, Inc. | Method for non-invasive electrical stimulation of epiphyseal plate growth |
US4487834A (en) * | 1982-09-17 | 1984-12-11 | Biolectron, Inc. | Electrical stimulation of articular chondrocytes |
US5269746A (en) * | 1982-12-20 | 1993-12-14 | Jacobson Jerry I | Therapeutic treatment of mammals for epilepsy and Parkinson's disease |
US4535775A (en) * | 1983-02-10 | 1985-08-20 | Biolectron, Inc. | Method for treatment of non-union bone fractures by non-invasive electrical stimulation |
IT1159024B (en) * | 1983-06-02 | 1987-02-25 | Ruggero Cadossi | METHOD AND DEVICE FOR THE TREATMENT OF FABRICS AND LIVING CELLS THROUGH ELECTROMAGNETIC FIELDS BUTTONS |
US4600010A (en) * | 1984-10-04 | 1986-07-15 | Biolectron, Inc. | Electric stimulator and test instrument therefor |
US5014699A (en) * | 1986-05-23 | 1991-05-14 | Trustees Of The University Of Pennsylvania | Electromagnetic method and apparatus for healing living tissue |
US6120502A (en) * | 1988-06-13 | 2000-09-19 | Michelson; Gary Karlin | Apparatus and method for the delivery of electrical current for interbody spinal arthrodesis |
US5038797A (en) * | 1990-02-20 | 1991-08-13 | Romaine, Incorporated | Electrical stimulation treatment device and method of use |
US5273033A (en) * | 1991-09-19 | 1993-12-28 | Murray Electronics Associates Limited Partnership | Electrical stimulation for treatment of osteoarthritis |
US5338286A (en) * | 1992-12-08 | 1994-08-16 | Electro-Biology, Inc. | Electromagnetic bioresponse by selective spectral suppression in pulsed field stimulation |
US5374283A (en) * | 1993-12-01 | 1994-12-20 | Flick; A. Bart | Electrical therapeutic apparatus |
US5743844A (en) * | 1996-11-01 | 1998-04-28 | Amei Technologies, Inc. | High efficiency pulsed electromagnetic field (PEMF) stimulation therapy method and system |
US6261221B1 (en) * | 1996-11-01 | 2001-07-17 | Amei Technologies Inc. | Flexible coil pulsed electromagnetic field (PEMF) stimulation therapy system |
US6132362A (en) * | 1996-11-01 | 2000-10-17 | Amei Technologies, Inc. | Pulsed electromagnetic field (PEMF) stimulation therapy system with bi-phasic coil |
US5968527A (en) * | 1997-02-27 | 1999-10-19 | Catholic University Of America, The | Protection of living systems from the adverse effects of stress |
US6083149A (en) | 1997-10-22 | 2000-07-04 | Emf Therapeutics, Inc. | Magnetic field device and method for inhibiting angiogenesis and retarding growth rates of tumors in mammals |
US6186940B1 (en) * | 1998-05-18 | 2001-02-13 | Robert N. Kirschbaum | Energized trace elements |
US6418345B1 (en) * | 1998-08-03 | 2002-07-09 | Amei Technologies Inc. | PEMF stimulator for treating osteoporosis and stimulating tissue growth |
WO2000066068A2 (en) * | 1999-04-29 | 2000-11-09 | North Shore Long Island Jewish Research Corporation | Method for inducing growth and enhancing survival of nervous tissue |
US6735468B2 (en) * | 2000-02-02 | 2004-05-11 | Massachusetts Institute Of Technology | Arthroscopic impedance probe to detect cartilage degeneration |
US7429471B2 (en) * | 2000-02-23 | 2008-09-30 | The Trustees Of The University Of Pennsylvania | Regulation of matrix metalloproteinase gene expression using specific and selective electrical and electromagnetic signals |
US7022506B2 (en) * | 2000-02-23 | 2006-04-04 | The Trustees Of The University Of Pennsylvania | Method and device for treating osteoarthritis, cartilage disease, defects and injuries in the human knee |
US7374916B2 (en) * | 2000-02-23 | 2008-05-20 | The Trustees Of The University Of Pennsylvania | Regulation of aggrecan gene expression using specific and selective electrical and electromagnetic signals |
US7465566B2 (en) | 2000-02-23 | 2008-12-16 | The Trustees Of The University Of Pennsylvania | Regulation of genes via application of specific and selective electrical and electromagnetic signals |
US6485963B1 (en) * | 2000-06-02 | 2002-11-26 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Growth stimulation of biological cells and tissue by electromagnetic fields and uses thereof |
AU2002227147A1 (en) * | 2000-11-02 | 2002-05-15 | Keith L March | Method and system for modulation of oscillating signals to enhance biologic effects |
US20030233124A1 (en) * | 2000-12-18 | 2003-12-18 | Hajuku Institute For Health Science Co., Ltd. | Methods of treating disorders by altering ion flux across cell membranes with electric fields |
KR100427405B1 (en) * | 2001-03-07 | 2004-04-17 | 박재만 | Pssc complex girder |
JP4801802B2 (en) | 2004-01-12 | 2011-10-26 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | Systems and methods for upregulating bone morphogenetic protein (BMP) gene expression in bone cells via application of electric fields generated by specific selective electrical and electromagnetic signals |
-
2004
- 2004-11-12 CA CA002545860A patent/CA2545860A1/en not_active Abandoned
- 2004-11-12 JP JP2006539935A patent/JP2007511289A/en active Pending
- 2004-11-12 US US10/579,174 patent/US20090062885A1/en not_active Abandoned
- 2004-11-12 MX MXPA06005358A patent/MXPA06005358A/en not_active Application Discontinuation
- 2004-11-12 EP EP04819117A patent/EP1689487A4/en not_active Withdrawn
- 2004-11-12 NZ NZ547198A patent/NZ547198A/en not_active IP Right Cessation
- 2004-11-12 AU AU2004291111A patent/AU2004291111A1/en not_active Abandoned
- 2004-11-12 US US10/987,866 patent/US7215995B2/en active Active
- 2004-11-12 WO PCT/US2004/037926 patent/WO2005049132A1/en active Application Filing
- 2004-11-12 CN CNA2004800372916A patent/CN1893999A/en active Pending
-
2006
- 2006-05-14 IL IL175619A patent/IL175619A0/en unknown
- 2006-06-14 NO NO20062787A patent/NO20062787L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US7215995B2 (en) | 2007-05-08 |
WO2005049132A1 (en) | 2005-06-02 |
EP1689487A1 (en) | 2006-08-16 |
NZ547198A (en) | 2008-05-30 |
NO20062787L (en) | 2006-08-14 |
CN1893999A (en) | 2007-01-10 |
AU2004291111A1 (en) | 2005-06-02 |
JP2007511289A (en) | 2007-05-10 |
IL175619A0 (en) | 2006-09-05 |
MXPA06005358A (en) | 2006-07-10 |
US20050177203A1 (en) | 2005-08-11 |
EP1689487A4 (en) | 2009-11-11 |
US20090062885A1 (en) | 2009-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7215995B2 (en) | Method and device for treating osteoarthritis and cartilage disease, defects, and injuries in the human hip | |
US7468264B2 (en) | Method and device for treating osteoarthritis, cartilage disease, defects and injuries in the human knee | |
US6919205B2 (en) | Regulation of type II collagen gene expression using specific and selective electrical and electromagnetic signals | |
USRE41391E1 (en) | Regulation of type II collagen gene expression using specific and selective electrical and electromagnetic signals | |
US7374916B2 (en) | Regulation of aggrecan gene expression using specific and selective electrical and electromagnetic signals | |
ZA200604880B (en) | Method and device for treating osteoarthritis and cartilage disease, defects, and injuries in the human hip |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |
Effective date: 20141121 |